Counterpoint: Were industry-sponsored rofl umilast trials appropriate

Jason Rho, Nancy Ho, Vinay Prasad

Research output: Contribution to journalArticle

6 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)939-942
Number of pages4
JournalChest
Volume145
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Scopolamine Derivatives
Benzamides
Aminopyridines
Phosphodiesterase 4 Inhibitors
Phosphodiesterase Inhibitors
Albuterol
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Industry
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Counterpoint : Were industry-sponsored rofl umilast trials appropriate. / Rho, Jason; Ho, Nancy; Prasad, Vinay.

In: Chest, Vol. 145, No. 5, 2014, p. 939-942.

Research output: Contribution to journalArticle

Rho, Jason ; Ho, Nancy ; Prasad, Vinay. / Counterpoint : Were industry-sponsored rofl umilast trials appropriate. In: Chest. 2014 ; Vol. 145, No. 5. pp. 939-942.
@article{ccd6b132978b4e8b967885dd329fdc56,
title = "Counterpoint: Were industry-sponsored rofl umilast trials appropriate",
author = "Jason Rho and Nancy Ho and Vinay Prasad",
year = "2014",
doi = "10.1378/chest.14-0114",
language = "English (US)",
volume = "145",
pages = "939--942",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Counterpoint

T2 - Were industry-sponsored rofl umilast trials appropriate

AU - Rho, Jason

AU - Ho, Nancy

AU - Prasad, Vinay

PY - 2014

Y1 - 2014

UR - http://www.scopus.com/inward/record.url?scp=84899832989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899832989&partnerID=8YFLogxK

U2 - 10.1378/chest.14-0114

DO - 10.1378/chest.14-0114

M3 - Article

C2 - 24798831

AN - SCOPUS:84899832989

VL - 145

SP - 939

EP - 942

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -